Omega-3 for Brain, Heart, and Vision: What the Claims Actually Mean
The three most commonly cited reasons for taking an omega-3 supplement are heart health, brain function, and vision. All three have EFSA-authorised health claims attached to them, which puts them in a different category from the vague "wellness" promises that dominate supplement marketing.
But the claims are specific, the intake conditions are precise, and the distinction between what is authorised and what is merely hoped for matters more than you might expect from the way products are marketed.
Heart Function
EPA and DHA contribute to the normal function of the heart. This is an EFSA-authorised health claim at a combined daily intake of 250 mg (Commission Regulation (EU) No 432/2012).
The word "contribute" is doing important work in that sentence. The claim is that adequate EPA+DHA intake supports normal cardiac function. It is not a claim that omega-3 prevents heart disease, reverses cardiovascular damage, or reduces your risk of a cardiac event. No such disease-risk-reduction claim is authorised for omega-3 at the standard intake level. If you see a supplement making that stronger claim, it has overstepped the evidence.
For you practically, the 250 mg threshold is the number to check against your supplement label. If your combined daily EPA+DHA intake reaches that level, you meet the condition for this claim.
If you eat oily fish twice a week, you are likely meeting it through diet. Without fish in your diet, you need a direct source: marine phytoplankton for EPA, algae oil for DHA, or a combination. We explain the sourcing options in our plant-based omega-3 guide.
Brain Function
DHA contributes to the maintenance of normal brain function, at a daily intake of 250 mg DHA. This is an EFSA-authorised claim, and the specificity matters: it is about DHA, not EPA, and it is about maintenance of normal function, not improvement or enhancement.
DHA is the most abundant omega-3 fatty acid in the brain, concentrated in the phospholipid membranes of neurons. This structural role is well-established in the scientific literature. What is less established is whether supplementing with DHA in adulthood produces measurable cognitive benefits in healthy people.
The EFSA claim is conservative for a reason: the evidence supports the importance of adequate DHA for your brain's normal function, not that additional DHA makes a healthy brain work better.
For anyone concerned about cognitive health, the honest framing is that adequate DHA intake appears to be part of the nutritional foundation for normal brain function. It is not a cognitive enhancer, and the claim does not extend to preventing or treating neurological conditions. If your DHA intake is already adequate, adding more may not produce a noticeable effect.
If you are plant-based, DHA is the harder fatty acid to source directly. Algae oil from Schizochytrium is the standard route: its fermentation process produces a predictable DHA-to-DPA ratio at scale, which is why we use it in our Clean Omega DHA rather than photosynthetic species that cannot match that consistency.
Vision
DHA contributes to the maintenance of normal vision, at a daily intake of 250 mg DHA. Same regulation, same intake condition as the brain-function claim.
DHA is a major structural component of the retina, particularly in the photoreceptor cells. This is why the vision claim is authorised alongside the brain-function claim: both relate to DHA's structural role in neural and sensory tissue.
The practical implication is the same: if your daily DHA intake reaches 250 mg, you meet the condition. The claim does not extend to improving vision, correcting visual impairment, or preventing age-related eye conditions. It is about maintaining the normal function of tissue that depends on DHA for its structural integrity.
Maternal and Infant Development
An additional set of claims applies during pregnancy and breastfeeding. Maternal DHA intake contributes to the normal development of the eye and brain of the foetus and breastfed infant. The condition is 200 mg DHA daily, on top of the recommended 250 mg EPA+DHA for adults.
This is one of the stronger evidence-backed use cases for DHA supplementation. The developing foetal brain has a high demand for DHA during the third trimester and early infancy. If you are pregnant or breastfeeding and not eating oily fish, algae-derived DHA is the plant-based route to meeting this condition — but discuss dosing with your GP or midwife before starting.
What Is Not Authorised
We covered the full list of unauthorised claims in our evidence hub. For brain, heart, and vision specifically:
- "Reduces the risk of heart disease" is not authorised at standard intake levels.
- "Improves memory" or "enhances cognitive performance" is not authorised.
- "Prevents macular degeneration" or "improves eyesight" is not authorised.
- "Reduces inflammation" is not authorised as a consumer health claim for EPA or DHA.
These are the claims you will encounter most frequently on the shelf, and all of them are beyond what the regulatory evidence supports. A product making any of these claims has overstepped the evidence. You deserve to know what a supplement can and cannot reliably do. We explain how we draw these lines in our evidence hub, and we apply the same standard to our own marketing.
The Practical Summary
If your goal is to meet the EFSA intake conditions for the heart, brain, and vision claims, you need 250 mg combined EPA+DHA daily (for heart) and 250 mg DHA specifically (for brain and vision). Those two targets can be met simultaneously if your total DHA intake is at least 250 mg and your combined EPA+DHA is also at least 250 mg.
Check your supplement label against these numbers using the guidance in our omega-3 label reading guide. The total omega-3 figure is not what matters. The individual EPA and DHA figures are.
What our research found
Two major cardiovascular trials gave opposite results. REDUCE-IT gave patients 4 g of pure EPA daily and found a 25 per cent reduction in cardiovascular events. STRENGTH gave patients a combination of EPA and DHA and was terminated early for futility. Whether DHA attenuates EPA's cardiovascular effect, or the mineral oil placebo in REDUCE-IT inflated the result, remains debated.
For brain function, the maintenance claim is better supported than the improvement claim. DHA comprises 40 per cent of brain cell membrane fatty acids. The EFSA claim is about maintaining normal function, not enhancing it. This is why we make no enhancement claims for Clean Omega DHA: the trial evidence in healthy adults does not consistently support them, though evidence is stronger in people with mild cognitive impairment.
The DHA source decision for our product came down to batch consistency. When we evaluated algae species for Clean Omega DHA, Schizochytrium produced a consistently predictable DHA-to-DPA ratio under fermentation conditions. Photosynthetic species we reviewed produced EPA as the dominant fatty acid, not DHA. That species split (one for EPA, a different one for DHA) is why we offer them as separate products rather than a blended formula.
Sources
- EFSA NDA Panel. Scientific Opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal cardiac function, blood pressure, and blood triglyceride concentrations. EFSA Journal. 2010;8(10):1796. EFSA
- EFSA NDA Panel. Scientific Opinion on the substantiation of health claims related to DHA and maintenance of normal brain function and normal vision. EFSA Journal. 2011;9(4):2078. EFSA
- Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Official Journal of the European Union. 2012;L136:1-40. EUR-Lex
- Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev. 2007;12(3):207-227. PubMed
Cara Hayes, MSc Nutrition and Dietetics (University of Sydney), writes all content in the Phytality Knowledge Centre. Read our editorial policy.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult your GP or a qualified healthcare professional before starting any supplement.
Methodology and Disclosure
Phytality manufactures EPA and DHA supplements from microalgae. We have a commercial interest in omega-3 supplementation. All health claims cited are from Commission Regulation (EU) No 432/2012 with stated intake conditions. The distinction between authorised and unauthorised claims reflects the regulatory register.
Biochemical role descriptions (DHA in brain membranes, retinal photoreceptors) reflect established nutrition science. Our assessment of the evidence reflects our editorial reading of the claim boundaries.
Last reviewed: March 2026
